Patents Assigned to Institute of Biophysics, Chinese Academy of Sciences
-
Patent number: 10195155Abstract: The present disclosure relates to a tumor-targeted drug delivery system, comprising a tumor-targeted drug carrier and a tumor-treating drug, wherein the tumor-targeted drug carrier comprises full heavy-chain human ferritin. The present disclosure also relates to a method for preparing the tumor-targeted drug delivery system comprising: depolymerizing a polymerized full heavy-chain human ferritin; adding a tumor-treating drug to the depolymerized full heavy-chain human ferritin so as to bind the tumor-treating drug to the depolymerized full heavy-chain human ferritin; and re-polymerizing the depolymerized full heavy-chain human ferritin bound with the tumor-treating drug to form a nanoparticle.Type: GrantFiled: September 24, 2014Date of Patent: February 5, 2019Assignee: Institute of Biophysics, Chinese Academy of SciencesInventors: Xiyun Yan, Kelong Fan, Minmin Liang, Fei Wang, Demin Duan, Dexi Zhang, Jing Feng, Dongling Yang
-
Publication number: 20180200223Abstract: The present invention provides applications of a small molecular flavonoid compound in preparing a medication for sensitizing/synergizing tumor radiation therapy as well as reducing radioactive damage. The small molecular flavonoid compound can be naringenin, hesperetin, luteolin and apigenin, etc. The medication contains a small molecular flavonoid compound and a plurality of conventional pharmaceutical additives; wherein the small molecular flavonoid compound is an active ingredient.Type: ApplicationFiled: August 25, 2016Publication date: July 19, 2018Applicant: INSTITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCESInventors: Wei LIANG, Chun Ling ZHANG, Wen Feng ZENG, Chao ZHANG, Luo Yang WANG
-
Patent number: 9899184Abstract: An optical vacuum cryostage for correlative light and electron microscopy comprises a vacuum chamber, an anti-contamination system adapter interface, an electron microscope specimen holder adapter interface, an upper optical window, a lower optical window, a vacuum pumping system adapter interface and a vacuum valve, wherein the anti-contamination system adapter interface is arranged in one end of the vacuum chamber, the electron microscope specimen holder adapter interface is arranged in the other end of the vacuum chamber, the upper optical window is arranged on the upper wall of the vacuum chamber, the lower optical window is arranged on the lower wall of the vacuum chamber and opposite to the upper optical window.Type: GrantFiled: July 22, 2015Date of Patent: February 20, 2018Assignee: Institute of Biophysics, Chinese Academy of SciencesInventors: Gang Ji, Shuoguo Li, Fei Sun
-
Publication number: 20180037617Abstract: The present invention relates to methods and compositions for treating and/or preventing a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, methods and compositions for diagnosis, prognosis or treatment monitoring of a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, and methods and compositions for identifying a modulator of the IFP35 family of proteins, including IFP35 and NMI.Type: ApplicationFiled: August 21, 2015Publication date: February 8, 2018Applicant: Institute of Biophysics, Chinese Academy of SciencesInventors: Yingfang LIU, Huanhuan LIANG, Juan SHEN, Zhikai XIAHOU
-
Publication number: 20170312352Abstract: Disclosed in the present invention is micellar polypeptide vaccine having pegylated phospholipid as carrier. The vaccine can prevent or treat tumors or can be used as combination formulation with anti-cancer activity formulation. The micellar polypeptide vaccine is formed of self-assembling pegylated phospholipid (PEG-PE) and antigenic polypeptides, the pegylated phospholipid being compound formed of polyethylene glycol (hydrophilic blocks) covalently bonded to nitrogenous bases on phospholipid molecule (hydrophobic blocks). The particle diameter of the micellar vaccine is 10-100 nm, and the antigenic polypeptides carried therein are polypeptides of 5-100 amino acids. The micellar polypeptide vaccine may also contain immunoadjuvant.Type: ApplicationFiled: October 19, 2015Publication date: November 2, 2017Applicant: INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCESInventors: Wei LIANG, Yan QIN
-
Publication number: 20170271126Abstract: An optical vacuum cooling cryostage for correlative light and electron microscopy comprises a vacuum chamber, an anti-contamination system adapter interface, an electron microscope specimen holder adapter interface, an upper optical window, a lower optical window, a vacuum pumping system adapter interface and a vacuum valve, wherein the anti-contamination system adapter interface is arranged in one end of the vacuum chamber, the electron microscope specimen holder adapter interface is arranged in the other end of the vacuum chamber, the upper optical window is arranged on the upper wall of the vacuum chamber, the lower optical window is arranged on the lower wall of the vacuum chamber and opposite to the upper optical window.Type: ApplicationFiled: July 22, 2015Publication date: September 21, 2017Applicant: INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCESInventors: Gang JI, Shuoguo LI, Fei SUN
-
Publication number: 20170189343Abstract: The present disclosure relates to a tumor-targeted drug delivery system, comprising a tumor-targeted drug carrier and a tumor-treating drug, wherein the tumor-targeted drug carrier comprises full heavy-chain human ferritin. The present disclosure also relates to a method for preparing the tumor-targeted drug delivery system comprising: depolymerizing a polymerized full heavy-chain human ferritin; adding a tumor-treating drug to the depolymerized full heavy-chain human ferritin so as to bind the tumor-treating drug to the depolymerized full heavy-chain human ferritin; and re-polymerizing the depolymerized full heavy-chain human ferritin bound with the tumor-treating drug to form a nanoparticle.Type: ApplicationFiled: September 24, 2014Publication date: July 6, 2017Applicant: Institute of Biophysics, Chinese Academy of SciencesInventors: Xiyun Yan, Kelong Fan, Minmin Liang, Fei Wang, Demin Duan, Dexi Zhang, Jing Feng, Dongling Yang
-
Publication number: 20160361334Abstract: Provided is an application of baicalin in preparation of a drug for treating ricin poisoning. A Hela cytoprotection test and a mouse ricin poisoning model have verified the recovery effect of baicalin on ricin poisoning.Type: ApplicationFiled: April 29, 2014Publication date: December 15, 2016Applicants: JILIN UNIVERSITY, INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCESInventors: Xuming DENG, Zihe RAO, Jing DONG, Xuemei LI, Yong ZHANG, Yutao CHEN, Jiazhang QIU
-
Publication number: 20160122719Abstract: The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac injuries and screening for new medicaments for treating cardiac injuries.Type: ApplicationFiled: October 28, 2015Publication date: May 5, 2016Applicant: Institute of Biophysics, Chinese Academy of SciencesInventor: Yue MA
-
Patent number: 9273286Abstract: The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac injuries and screening for new medicaments for treating cardiac injuries.Type: GrantFiled: November 11, 2010Date of Patent: March 1, 2016Assignee: Institute of Biophysics, Chinese Academy of SciencesInventor: Yue Ma
-
Publication number: 20150299658Abstract: Provided in the present invention is a method for inducing pluripotent stem cells to differentiate into ventricular myocytes in vitro, which is achieved by maintaining, amplifying and culturing pluripotent stem cells in vitro, adding a substance capable of activating the Smad1/5/8 signaling pathway directly or indirectly into the culture medium when pluripotent stem cells are in the middle stage of myocardial differentiation, i.e. the period of differentiating into cardiac muscle cells from mesoderm cells or myocardial precursor cells, which enables stem cells to differentiate into ventricular myocytes directionally.Type: ApplicationFiled: July 22, 2013Publication date: October 22, 2015Applicant: Institute of Biophysics, Chinese Academy of SciencesInventor: Yue MA
-
Patent number: 9073995Abstract: Provided in the present invention are an aberrantly glycosylated integrin, AG-?3?1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-?3?1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer.Type: GrantFiled: August 12, 2011Date of Patent: July 7, 2015Assignee: Institute of Biophysics, Chinese Academy of SciencesInventors: Chong Li, Zusen Fan, Honglian Zhang, Zhonghua Dai, Haidong Tang, Jun Chen
-
Crystal structure of amino terminal portion of influenza virus polymerase PA subunit and use thereof
Patent number: 9017960Abstract: Present invention discloses the three-dimensional crystal structure of the N-terminus polypeptide of influenza virus polymerase subunit (PA_N of SEQ ID NO:7). PA_N of SEQ ID NO: 1 is residues 1—50 to 150-300 of influenza virus polymerase subunit PA. In the three-dimensional structure, at least 40% of atoms show the same atomic coordinates, compared to that listed in Table 1. Namely, in the three-dimensional structure of influenza virus polymerase subunit PA_N of SEQ ID NO: 7, 40% of atomic coordinates on carbon skeleton of residues of influenza virus polymerase subunit PA_N of SEQ ID NO: 7, show less than or equal to 1.7 ? of average variance, compared to the atomic coordinates listed in Table 1. Present invention also discloses the expression, purification, crystallization methods, and three-dimensional crystal structure of 256 residues in the N-terminus of influenza virus polymerase subunit PA, and applications of the crystal structure of SEQ ID NO: 7 on drug screening and designing.Type: GrantFiled: February 3, 2010Date of Patent: April 28, 2015Assignee: Institute of Biophysics Chinese Academy of SciencesInventors: Yingfang Liu, Zihe Rao -
Publication number: 20130164216Abstract: Provided in the present invention are an aberrantly glycosylated integrin, AG-?3?1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-?3?1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer.Type: ApplicationFiled: August 12, 2011Publication date: June 27, 2013Applicant: Institute Of Biophysics, Chinese Academy Of SciencesInventors: Chong Li, Zusen Fan, Honglian Zhang, Zhonghua Dai, Haidong Tang, Jun Chen
-
Crystal Structure of Amino Terminal Portion of Influenza Virus Polymerase PA Subunit and Use thereof
Publication number: 20130046076Abstract: Present invention disclosed three-dimensional crystal structure of N-terminus polypeptide of influenza virus polymerase subunit (PA_N). PA_N is residues 1˜50 to 150˜300 of influenza virus polymerase subunit PA. In three-dimensional structure, at least 40% of atoms showed same atomic coordinates, compared to that listed in Table. In other words, in three-dimensional structure of influenza virus polymerase subunit PA_N, 40% of atomic coordinates on carbon skeleton of residues of influenza virus polymerase subunit PA_N, showed less than or equal to 1.7 ? of average variance, compared to the atomic coordinates listed in Table1. Present invention also disclosed the expression, purification, crystallization methods, and three-dimensional crystal structure of 256 residues in the N-terminus of influenza virus polymerase subunit PA, and applications of the crystal structure on drug screening and designing.Type: ApplicationFiled: February 3, 2010Publication date: February 21, 2013Applicant: Institute of Biophysics Chinese Academy of SciencesInventors: Yingfang Liu, Zihe Rao -
Patent number: 8143044Abstract: Provided are the expression method of influenza virus polymerase PAc-PB1N complex, the co-crystallization method of the complex and the three-dimendional structure of the crystal of PAc-PB1N complex. Also provided are the compounds binding to the influenza virus polymerase PAc and the expression method of influenza virus polymerase PAN. The three-dimensional structure of the crystal of PAc-PB1N complex can be used for screening and designing the drug for the treatment of influenza.Type: GrantFiled: February 22, 2009Date of Patent: March 27, 2012Assignee: Institute of Biophysics Chinese Academy of SciencesInventors: Yingfang Liu, Xiaojing He, Zonghao Zeng, Jie Zhou
-
Patent number: 7794996Abstract: This invention provides recombinant murine leukemia virus reverse transcriptases, genes encoding these proteins and expression methods. The said murine leukemia virus reverse transcriptases are a series of MLV-RT proteins wherein the 84th amino acid residue (Q84) from the N-terminus is replaced with amino acid X, which is an amino acid with a side chain shorter than glutamine. The said murine leukemia virus reverse transcriptases have higher enzyme activity and processivity than the wild type enzyme, and are expected to be widely used in the field of biotechnology for cDNA synthesis.Type: GrantFiled: January 13, 2004Date of Patent: September 14, 2010Assignee: The Institute of Biophysics, Chinese Academy of SciencesInventors: Guangxia Gao, Shufeng Liu
-
Patent number: 7785774Abstract: A regulable molecular motor micropower biosensor comprises: a rotary motor, an optical energy conversion device, a signal molecular output device, a power resource system, a protective layer, a supporting material, and a bilayer lipid membrane fixing material. The molecular motor micropower biosensor is used for detecting biological macromolecules, viral molecules, etc.Type: GrantFiled: December 15, 2005Date of Patent: August 31, 2010Assignee: Institute of Biophysics, Chinese Academy of SciencesInventor: Jiachang Yue
-
Publication number: 20090275052Abstract: A regulable molecular motor micropower biosensor comprises: a rotary motor, an optical energy conversion device, a signal molecular output device, a power resource system, a protective layer, a supporting material, and a bilayer lipid membrane fixing material. The molecular motor micropower biosensor is used for detecting biological macromolecules, viral molecules, etc.Type: ApplicationFiled: December 15, 2005Publication date: November 5, 2009Applicant: INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCESInventor: Jiachang Yue
-
Publication number: 20090232900Abstract: The present invention provides a nano-micellar preparation of anthracycline antitumor antibiotics for intravenous injection, which comprises a therapeutically effective amount of anthracycline antitumor antibiotics, a phosphatide derivatized with polyethylene glycol, together with pharmaceutically acceptable adjuvants. The preparation is prepared by encapsulating the medicament with a nano-micelle to obtain the nano-micellar preparation of anthracycline antitumor antibiotics for injection. The anthracycline antitumor antibiotics and the phosphatide derivatized with polyethylene glycol form a nano-micelle with a highly homogeneous particle size.Type: ApplicationFiled: June 24, 2005Publication date: September 17, 2009Applicant: Institute of Biophysics, Chinese Academy of SciencesInventors: Wei Liang, Ning Tang, Chunling Zhang, Zihe Rao